Sonoma Biotherapeutics
Katie brings to Sonoma a strong background in cellular assay development, as well as training in virology and immunology. She completed a B.S. at the University of Washington in Biochemistry and Microbiology, then continued on to earn a Ph.D. in Molecular and Cellular Biology in the laboratory of Jesse Bloom, studying a novel influenza virus entry mechanism and its consequence on humoral immunity.
Prior to joining Sonoma, she spent 4 years with Bluebird Bio working to develop assays to characterize the function and potency of CAR- and transgenic TCR-T cells. She was also extensively involved in Bluebird’s gene-editing platform and its application to the oncology pipeline. Prior to Bluebird, she completed a postdoctoral fellowship at the California Institute for Biomedical Research where she worked on the switchable CAR-T cell platform, now partnered with Abbvie for clinical development.
Katie is a member of Sonoma’s Translational Development team in Seattle and will be working to characterize the cell therapy products as they develop for the clinic.
This person is not in any offices
Sonoma Biotherapeutics
1 followers
Sonoma Biotherapeutics is developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases driven by an imbalanced immune system. Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted Treg cell therapies designed to induce durable immune tolerance to treat and prevent autoimmune and inflammatory diseases. Sonoma Biotherapeutics is based in South San Francisco and Seattle.